Geoffrey Shapiro, M.D., Ph.D.

Scientific Advisory Board

Dr. Shapiro currently serves as Director, Early Drug Development Center and Clinical Director, Center for DNA Damage and Repair, and an Institute Physician at the Dana-Farber Cancer Institute. His research focuses on the investigation of the role of cell cycle and DNA repair-related proteins in a variety of solid tumors, including breast, ovarian, pancreatic and lung, with clinical interests in developmental therapeutics and Phase I clinical trials. He is also a Professor of Medicine at Harvard Medical School and serves as the Principal Investigator on the National Cancer Institute/Clinical Trials Evaluation Program (NCI/CTEP) Early Therapeutics UM1 Grant for Dana-Farber/Harvard Cancer Center.  He is a member of the NCI Investigational Drug Steering Committee and has served on scientific committees of both the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), as well as the European Society of Medical Oncology (ESMO) International Congress on Targeted Anticancer Therapies. Dr. Shapiro holds Ph.D. and M.D. degrees from Cornell University, and completed his postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he served as chief medical resident, followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute.

5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731